Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.37
-0.01 (-3.28%)
Market open: Aug 12, 2026, 11:15 AM EDT
0.40
+0.01 (3.63%)
Previous after-hours: Aug 11, 2026, 7:49 PM EDT
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.
| Name | Position |
|---|---|
| Dr. Constance Hofer | Chief Scientific Officer |
| Mr. Chankyu Park | Chief Executive Officer of RMC |
| Mr. Gihyoun Bang | Chief Financial Officer |
| Mr. Jun Chul Whang | Chief Legal Officer, Secretary & Director |
| Mr. Kuk Hyoun Hwang | Chairman & CEO |
| Mr. Senyon Choe | Founder & CEO of Darnatein |
| Mr. Tim Smith | Corporate Secretary & Global IR |
| Mr. Yeiseok Kim | Chief Operating Officer |
| Date | Type | Document |
|---|---|---|
| 2026-08-10 | 8-K | ea0301344-8k_osrhealth.htm |
| 2026-08-07 | 8-K | ea0301114-8k_osrhealth.htm |
| 2026-07-31 | 8-K | ea0300111-8k_osrhealth.htm |
| 2026-07-16 | DEF 14A | ea0296871-02.htm |
| 2026-07-06 | PRE 14A | ea0296871-01.htm |
| 2026-06-17 | 8-K | ea0295099-8k_osrhealth.htm |
| 2026-06-11 | DEFA14A | ea0294459-defa14a_osr.htm |
| 2026-06-11 | 8-K | ea0294460-8k_osrhold.htm |
| 2026-06-02 | 8-K | ea0293037-8k_osrhold.htm |
| 2026-05-26 | DEF 14A | ea0288424-02.htm |